Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by mercedesmanon Feb 09, 2023 8:21am
87 Views
Post# 35276554

RE:The stars were aligned

RE:The stars were aligned

A brutal Qtr for sure!

$50M ( let alone $100M) in annualized sales , seems a long way off from here. 

Other markets ( besides ON) need to be opened up, in particular for VTM.  Has rapid testing completely killed the need or is there now general overcapacity? Commentary and or a response strategy needs to be articulated. 

unfortunate QAP orders are delayed. Difficult to establish a go forward run rate  from here. More visibility needed  

Now might be a good time to find a partner on Kinlytic and to find a future revenue stream that investors can get excited about. 

Multiplexing also an exciting opportunity that has growth potential. 

Not throwing in the towel but Mgt needs to establish in investors minds that this Qtr is an anomaly  

MM 

 

<< Previous
Bullboard Posts
Next >>